Stony Brook University is actively seeking companies interested in licensing a *Francisella tularensis* infection-derived monoclonal antibody for use in detecting infectious diseases and bioterrorism agents related to tularemia.

**Technology Description:**

*Francisella tularensis* is an intracellular, gram-negative bacterium that primarily invades macrophages and attacks the human immune system. Tuleremia, commonly known as “rabbit fever” can be communicated across several species including rabbits, rodents and humans. Developed by Jorge L. Benach, Ph.D., director of the Center for Infectious Diseases in the Centers for Molecular Medicine, and chair of the Department of Molecular Genetics and Microbiology at Stony Brook University, this murine monoclonal antibody recognizes a native epitope of *Francisella tularensis* “Live Vaccine Strain”; monoclonal antibody clone 105 against a native epitope of *Francisella tularensis* protein, LpnA/Tu14. Additional research efforts may reveal this antibody’s involvement in the attenuation of bacterial infection.

**Applications:**
- Western blot
- ELISA
- Immunoprecipitation
- Immunofluorescence assays

**Publications:**

**Jennifer Hsieh**
Assistant Director for Life Sciences
Office of Technology Licensing & Industry Relations
N5002 Melville Library
Stony Brook University
Stony Brook, NY 11794-3369
631-632-1361 (voice)
ShiuYie.Hsieh@stonybrook.edu
www.stonybrook.edu/research/otlr